Abstract-Atherosclerosis is the leading cause of cardiovascular morbidity and mortality. Over the past 2 decades, increasing research attention is converging on the early detection and monitoring of atherosclerotic plaque. Among several invasive and noninvasive imaging modalities, magnetic resonance imaging (MRI) is emerging as a promising option. Advantages include its versatility, excellent soft tissue contrast for plaque characterization and lack of ionizing radiation. In this review, we will explore the recent advances in multicontrast and multiparametric imaging sequences that are bringing the aspiration of simultaneous arterial lumen, vessel wall, and plaque characterization closer to clinical feasibility. We also discuss the latest advances in molecular magnetic resonance and multimodal atherosclerosis imaging.
C ardiovascular disease remains the leading cause of mortality worldwide, with expected direct and indirect costs of $1.1 trillion by 2035 in the United States alone.
1 Coronary artery disease (CAD) and stroke are the 2 biggest contributors to cardiovascular disease (44% and 17%, respectively 1 ), with atherosclerosis being the common pathological process between them.
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Please see https://www.ahajournals.org/atvb/atvbfocus for all articles published in this series.
Atherosclerosis is defined as the gradual buildup of plaque (a heterogeneous collection of fat, calcium, fibrous tissue, components of the immune system, and other materials) within the arterial wall. 3, 4 This process is accelerated and influenced by repeated endothelial/vascular injury and inflammation. 2, 3 As the plaque progressively grows in size, the vessel lumen may become obstructed (negative remodeling), leading to chronically reduced blood flow to the target organ. 2, 4 Rupture and thrombosis of the plaque can cause acute vessel lumen obstruction and embolization, leading to devastating consequences such as acute myocardial infarction and stroke 2, 4 and often occurs in nonstenotic vessels without any prior symptoms.
The early detection and long-term monitoring of atherosclerosis enable targeted risk stratification and prophylactic treatment of patients most at risk of developing ischemic cardiovascular disease. While the atherosclerotic process can affect any artery within the body, including coronary, carotid, peripheral, and renal arteries, in this review article, we will focus on the imaging modalities for atherosclerosis in the coronary and carotid arteries with a particular focus on the emergence of magnetic resonance imaging (MRI) in this field.
Invasive X-ray angiography remains the gold standard imaging modality for coronary and carotid artery imaging. [5] [6] [7] However, complications (such as death, stroke, myocardial and vascular injury, pain and bleeding), ionizing radiation, contrast-mediated nephropathy, and inability to characterize soft tissue limit its capacity as a monitoring and screening tool for atherosclerosis.
Intravascular imaging (intravascular ultrasound and optical coherence tomography [OCT] ) provides real-time assessment of vessel wall and plaque composition (lipid core, thrombus, hemorrhage, fibrous tissue, calcium, and thin-cap fibroatheroma). 8, 9 However, OCT is reliant on iodine-based contrast agents, 8, 9 and both carry the risk of invasive coronary complications and are not recommended for routine stable plaque assessment.
Computed tomography (coronary/carotid) angiography (CTCA/CTA) allows a 3-dimensional (3D) depiction of the entire coronary, carotid and cranial circulation with high temporal and spatial resolution. CTCA/CTA is the noninvasive imaging alternative of choice to invasive X-ray angiography in patients with suspected carotid artery disease or stable CAD at low-intermediate risk. 7, [10] [11] [12] [13] [14] [15] Further technological advances have enabled fractional flow reserve and atherosclerotic plaque (overall plaque burden, spotty calcification, plaque attenuation pattern, and positive remodeling index) assessment. [11] [12] [13] [14] However, the risk from ionizing radiation, contrast-mediated nephropathy, and blooming artifact in advanced plaque calcification limit the use of CTCA/CTA as a monitoring tool for atherosclerotic progression. 7, 16 The drawbacks of the above imaging modalities have motivated the development of MR technology over the past 2 decades. Cardiovascular MR is a safe, versatile, and noninvasive imaging modality, which is free of harmful ionizing radiation and iodinated contrast agents. Combined with excellent soft tissue characterization, MRI is uniquely positioned to establish itself as an alternative imaging modality for the early detection, risk stratification and long-term monitoring of arterial atherosclerosis.
The various stages of atherosclerosis and the role of various imaging modalities for lumen and plaque assessment are shown in Figure 1 .
Rational for Noninvasive Early Plaque Characterization
During the early phase of atherosclerotic disease, compensatory arterial mechanisms consist of both vessel wall and luminal enlargement. 17, 18 However, previous studies have shown that positive arterial remodeling is associated with increased plaque vulnerability and rupture. [19] [20] [21] [22] Indeed, angiographically normal carotid and coronary arteries do not exclude extensive underlying atherosclerosis. [23] [24] [25] Furthermore, intensive early treatment of positive remodeling has been shown to reduce plaque burden and cardiovascular risk.
26,27 Therefore, attention is shifting towards vessel wall depiction and plaque characterization in conjunction with luminography to provide a more comprehensive and accurate representation of atherosclerosis.
Coronary MR Plaque Characterization
The potential of coronary MR angiography (CMRA) has been examined in patients with CAD, demonstrating a negative predictive value of up to 88% versus X-ray angiography.
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Prospectively, significant coronary stenosis on CMRA has been shown to be significantly associated with cardiac events (cardiac death, myocardial infarction, unstable angina, and revascularization >90 days after CMRA). 29 Despite this, widespread clinical implementation is hampered by long acquisition times, complex scan planning, lower spatial resolution, and motionrelated image quality degradation. However, with excellent soft tissue differentiation and vessel wall depiction, as well as recent advances in motion correction, image acceleration and reconstruction techniques, MR coronary lumen and plaque imaging is attracting considerable research interest. A detailed discussion on CMRA is beyond the scope of this review however further details can be found in the selected articles.
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In a landmark study in 2000, Fayad et al 33 proved the feasibility of 2-dimensional (2D) black-blood MRI to depict coronary vessel wall and positive arterial remodeling. Shortly afterwards, Botnar et al 34, 35 extended this to free-breathing and 3D coronary vessel wall imaging. 36 In a MESA (Multi-Ethnic Study of Atherosclerosis) involving 179 asymptomatic participants, Miao et al 37 were able to demonstrate positive remodeling using coronary cross-sectional vessel size, lumen area, and mean wall thickness using black-blood MRI. More recently, Andia et al 38 and Cruz et al 39 were able to develop flow independent coronary vessel wall imaging and applied advanced image acceleration and motion correction techniques to successfully enable simultaneous acquisition of coronary lumen and vessel wall depiction with ≈100% respiratory scan efficiency and thus shorter and predictable scan times.
Features of vulnerable plaque include a large lipid-pool, thin-cap fibroatheroma, macrophage accumulation, intraplaque hemorrhage, 40 and thrombus. Noncontrast T1-weighted MRI has been used in several studies to identify vulnerable coronary plaques as validated with OCT.
41-54 These appear as high-intensity signals (often termed high-intensity plaques [HIP] ) and the signal intensity can be categorically quantified. 55 Indeed, previous studies have shown that HIP imaged with noncontrast T1-weighted MRI was significantly associated with future coronary events, independent of the degree of coronary lumen stenosis; providing a potential tool for the early identification, risk stratification, and treatment of patients at risk of CAD. 41, 46 In fact, the AQUAMARINE pilot study (Attempts at Plaque Vulnerability Quantification with Magnetic Resonance Imaging Using Noncontrast T1-weighted Technique) demonstrated significant reduction in HIP signal intensity in patients treated with 12 months of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) compared with controls (P<0.001). 47 The same group are currently recruiting for the AQUAMARINE EPA/DHA study (Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary HIPs detected with noncontrast T1-weighted imaging). 56 This is a randomized controlled trial aiming to assess 43 One theory is that T1-weighted imaging exploits the short T1 of methemoglobin that is present in an acute thrombus and intraplaque hemorrhage. 54, 57 In a Japanese case report of a patient undergoing elective PCI, after balloon dilation, aspirated specimen from the HIP site on MRI showed a large amount of necrotic core with overlying platelet and brim-rich thrombus, while immunohistology confirmed numerous CD68+ macrophages. 50 More recently, in a study of 7 patients undergoing coronary endarterectomy and coronary artery bypass grafting, ex vivo T1-weighted MRI scans were performed on the surgically removed coronary plaques with histological matching. 58 None of the ex vivo plaques demonstrated high-intensity signal on MRI (on bright-blood, black-blood, T1-or T2-weighted images) and there was no evidence of intraplaque hemorrhage on histology. However, these plaques were obtained from severely stenotic or occlusive fibrotic lesions, representing the most advanced stage of atherosclerosis, and may not have been suitable for MRI detection. 58, 59 The majority of the T1-weighted MRI plaque characterization studies relied on separate acquisition of T1-weighted images followed by CMRA acquisition as an anatomic reference to register the T1-weighted signal to the exact location in the coronary tree. The clinical feasibility of this approach is hampered by several limitations. First, the sequential acquisition of T1-weighted and CMRA images prolongs the scan time and can lead to misregistration artifacts. 48 Second, 1-dimensional diaphragmatic navigator respiratory motion correction and gating leads to long and unpredictable scan times, largely determined by the breathing pattern of the patient. 48 Third, increased patient movement associated with prolonged scanning times may lead to degraded image quality with lower spatial resolution. 48 To overcome these limitations, Xie et al 48 recently proposed the coronary atherosclerosis T1-weighted characterization with integrated anatomic reference (CATCH) sequence. By acquiring a black-blood inversion recovery sequence and an anatomic bright-blood reference in an interleaved fashion, combined with advanced motion correction and image acceleration techniques, they were able to acquire simultaneous bright-blood CMRA (at 1.1 mm spatial resolution) with blackblood T1-weighted images for plaque characterization in ≈10 minutes, with 100% respiratory scan efficiency and predictable scan time. Using OCT as the gold standard in vivo validator, they showed that patients with higher plaque signal intensity on T1-weighted MRI had significantly more lipids, macrophages, and cholesterol crystals within their coronary plaques.
However, in the CATCH sequence, the MRI reconstruction relies on respiratory motion parameters that are partially shared among the bright-blood and the black-blood data. Therefore, HIP and CMRA misregistration may not be entirely avoided. 57 Furthermore, the absence of preparatory pulses before the acquisition of the bright-blood anatomic reference scan may lead to suboptimal image contrast, in comparison with a dedicated CMRA sequence, reducing its diagnostic value. 57 To overcome some of the limitations of the CATCH sequence, Ginami et al 57 recently introduced the 3D whole-heart noncontrast enhanced bright-blood and black-blood phasesensitive inversion recovery sequence for simultaneous coronary lumen and coronary thrombus/intraplaque hemorrhage visualization. This is achieved by alternating the acquisition of 2 different bright-blood datasets, which are then combined in a phase-sensitive inversion recovery-like reconstruction to obtain a third, black-blood dataset. The 2 differently weighted bright-blood datasets enable coronary lumen visualization and allow a respiratory motion to be independently estimated and corrected, further reducing the probability of misregistration artifacts. Furthermore, the coregistered black-blood phase-sensitive inversion recovery dataset enables thrombus and intraplaque hemorrhage visualization. Combined with 2D image navigators and advanced image acceleration and motion correction techniques, the bright-blood and blackblood phase-sensitive sequence was superior to conventional CMRA in terms of signal-to-noise ratio and vessel sharpness, with a spatial resolution of 1 mm. Furthermore, its feasibility for thrombus detection was tested in an ex vivo pig model. The same bright-blood and black-blood phase-sensitive sequence can be also acquired after contrast injection to enable simultaneous coronary lumen visualization and late gadolinium enhancement contrast-enhanced (CE) black-blood myocardial tissue characterization in a single, free-breathing multicontrast whole-heart acquisition with 100% respiratory scan efficiency and predictable scan time. 60 Bright-blood and black-blood phase sensitive has been recently combined with acceleration techniques to enable acquisition times of ≈8 minutes for both bright-and black-blood data sets 61 for 1 mm spatial resolution. However, it has yet to be validated clinically for coronary plaque characterization (intraplaque hemorrhage and thrombus).
In a preliminary study of 9 patients with CAD, Maintz et al 51 showed that it is feasible to differentiate between plaque types (calcified, noncalcified, and mixed calcified) also using a CE inversion recovery sequence. However, this study used CTCA as a reference standard and did not include histological validation. Similar results were obtained by Yeon et al 52 in a subsequent study of 14 patients with CAD. In a study of 10 patients with acute myocardial infarction and 9 patients without CAD, CE inversion recovery CMRA showed significant enhancement in the vessel wall and stenotic segments of patients immediately after acute myocardial infarction, with the subsequent significant reduction in enhancement 3 months after the event. 53 This correlated with a reduction in CRP (C-reactive protein) levels, suggesting edema or inflammation during the postinfarction phase. Similarly, Schneeweis et al 62 discovered that CE inversion recovery CMRA showed significant coronary vessel wall enhancement in patients with stable CAD and in patients with inflammatory Takayasu arteritis. No enhancement was observed before contrast in either group.
Carotid MR Plaque Characterization
Unlike in CAD, MRA is a clinically validated and established imaging modality for assessment of carotid stenosis. 7, 63 This is because carotid arterial imaging does not suffer from the same degree of motion artifacts (especially cardiac and respiratory motion). The imaging technique used is either timeof-flight-MRA without contrast administration and taking advantage of physical features of flowing blood or CE-MRA using intravenously administered gadolinium contrast agent. 7, 63 Indeed, in a study of 2404 patients with carotid artery stenosis (70%-99%), CE-MRA was more accurate than time-offlight-MRA, ultrasound and CTA, with a sensitivity of 94% and specificity of 93%. 64 Over the past 2 decades, the feasibility of multicontrast MRI (time-of-flight, proton density, and T1 and T2 weighted) for carotid plaque characterization has been established. Furthermore, CE T1-weighted MRA has been shown to increase the delineation of plaque components (such as fibrous tissue and lipid core) compared with unenhanced MRI. 65, 66 In addition, dynamic CE-MRI of atherosclerotic plaque allows assessment of neovascularization, inflammation, and permeability. 65, 67 With histological validation, early and advanced plaque features can be distinguished with regards to their MRI contrast enhancement, for example, lipids and necrotic core (T1W and CE-MRI), 68 fibrous cap (T1W and CE-MRI), 69 calcification (T1W, CE, proton density weighting-MRI), 68 inflammation (T1W and CE-MRI), 67 and intraplaque hemorrhage (T1W-MRI) 70, 71 ( Figure 1 ). Several studies have reported worse clinical outcomes in patients with features of vulnerable plaque on carotid MRI. [72] [73] [74] [75] [76] [77] Of these, the presence of intraplaque hemorrhage is clinically significant as it represents American Heart Association type VI advanced plaque. 78 In addition, its presence on MRI is associated with accelerated plaque progression on serial MRI scans. 79 In a study of 29 patients (14 cases with intraplaque hemorrhage and 15 controls with comparably sized plaques without intraplaque hemorrhage) with serial carotid plaque MRI scans, the presence of intraplaque hemorrhage at baseline was significantly associated with increased vessel wall volume (P=0.009), lipid-rich necrotic core volume (P=0.001), and new intraplaque hemorrhages (P=0.006) at 18 months. 72 Furthermore, multiple studies have demonstrated the presence of carotid intraplaque hemorrhage is significantly associated with future stroke risk. In a prospective study of 179 symptomatic patients with >50% carotid stenosis, intraplaque hemorrhage on MRI was significantly associated with recurrent ischemic events (hazard ratio, 12.0; 95% CI, 4.8-30.1; P<0.001) and stroke (hazard ratio, 35.0; 95% CI, 4.7-261.6, P=0.001). 80 In a systematic review of 689 patients, the presence of carotid intraplaque hemorrhage on baseline MRI was associated with a 6-fold increase in future cerebrovascular events. 81 In a separate systematic review of 779 patients, carotid intraplaque hemorrhage on MRI was significantly associated with future stroke or transient ischemic attack (hazard ratio, 4.59; 95% CI, 2.91-7.24). 82 Furthermore, it has been shown that treatment with statins significantly reduces plaque ruptures, lumen thrombi, intraplaque hemorrhages, intraplaque microvessels, and inflammatory cells on histological analysis. 83 In a separate analysis of 1740 patients from the Rotterdam Study who had carotid MRI scans, statin treatment seemed to shift the plaque composition by lowering the levels of lipid core and increasing calcification. 84 Several other studies have confirmed on serial MRI scans that statin treatment (with increasing dose and duration) is associated with reductions in plaque vascularity, lipid core, and in some cases plaque volume. [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] Few studies have looked at the effect of antiplatelets on carotid plaque progression. In a study of 100 patients with symptomatic carotid stenosis, the previous use of antiplatelet agents was associated with carotid intraplaque hemorrhage on MRI, 97 prompting concern about the prophylactic use of antiplatelets in asymptomatic patients. In another study, the use of dual antiplatelet therapy was an independent risk factor for progression to severe carotid artery stenosis (>70%) in asymptomatic patients. 98 However, in another study, cilostazol therapy (an antiplatelet) was associated with increased fibrotic plaque material and decreased lipid/necrotic components on MRI, 99 potentially stabilizing the plaque structure. Despite the early promise, clinical integration of these MR carotid plaque characterization sequences has been challenging for several reasons. First, the large slice thickness of 2D black-blood sequences hampers reliable detection of plaque components, reduces reproducibility and leads to repositioning errors in serial imaging. 100, 101 Second, the sequential acquisition of multicontrast MRI (time-of-flight, proton density, T1 and T2 weighted, etc) is time-consuming with scan times of up to 30 minutes, increasing cost and patient inconvenience. 102, 103 Third, the long acquisition time increases the likelihood of motion and misregistration artifacts because of patient movement. 102, 103 Finally, complex image interpretation of signal patterns on multicontrast weightings has limited the widespread clinical application of these sequences. 102, 103 Several technical breakthroughs over the past decade have enabled some of these challenges to be overcome. It was quickly realized that to overcome the relatively large slice thickness of 2D sequences, and to truly assess plaque in tortuous carotid arteries, 3D imaging sequences needed to be used. Several studies demonstrated the possibility of rapid 3D acquisition of carotid lumen and vessel wall morphology. [104] [105] [106] [107] [108] [109] For instance, the 3D motion-sensitized driven equilibrium rapid gradient echo (3D-MERGE) sequence enabled isotropic high spatial resolution (0.7×0.7×0.7 mm) coverage of the entire carotid arteries within 2 minutes, validated in patients with significant carotid plaques. 107 It was also generally agreed that image contrast should be tailored to major plaque components to simplify the image interpretation process. Exploiting the shortening effect of methemoglobin on T1 relaxation time, Moody et al 110 introduced the T1-weighted magnetization prepared 3D Gradient Echo sequence (MP-RAGE), which was highly selective for intraplaque hemorrhage. 111 This sequence was further optimized by Wang et al 112 to improve the contrast between intraplaque hemorrhage, vessel wall, and lumen, by using a slab-selective phase-sensitive inversion-recovery technique. Wang et al 113 further modified the slab-selective phase-sensitive inversionrecovery technique and in 2013 introduced the novel simultaneous noncontrast angiography and intraplaque hemorrhage (SNAP) technique that allowed both MRA and intraplaque hemorrhage evaluations in the same acquisition (≈5 minutes). SNAP works by generating negative magnetization after an initial inversion pulse to produce bright-blood images (corresponding to MRA). After a certain delay time, intraplaque hemorrhage is seen as a bright signal (positive magnetization) and other tissue is suppressed. In a later comparative study with contrast-enhanced MRA, the SNAP sequence showed excellent agreement (intraclass correlation coefficient: 0. Recently, the CATCH sequence developed for coronary plaque imaging was extended to the carotids. 58 Using histology validation, in an in vivo and ex vivo study of 12 patients undergoing carotid endarterectomy, the CATCH sequence was significantly more sensitive for intraplaque hemorrhage than conventional T1-and T2-weighted sequences (sensitivity, specificity, and κ value were 76.7%, 95.3%, and 0.75 for in vivo T1-weighted imaging, 77.2%, 97.4%, and 0.78 for ex vivo T2-weighted imaging, and 95.0%, 92.1%, and 0.84 for ex vivo CATCH, respectively). Other dual contrast techniques include the black-blood and gray blood sequence that is able to simultaneously image the vessel lumen and wall, while identifying plaque calcification much more distinctively compared with conventional MRI scans. 117 Combining T1-weighted, gray blood, and T2-weighted imaging into a single simultaneous multicontrast scan in <5 minutes, Fan et al 102 proposed the multicontrast atherosclerosis characterization sequence. It uses a 3D spoiled segmented fast low angle shot readout to acquire data with 3 different contrast weightings in an interleaved fashion. This enables simultaneous detection of intraplaque hemorrhage, calcification, lipid-rich necrotic core, and loose matrix. After an initial feasibility study, 102 multicontrast atherosclerosis characterization was shown to be at least comparable if not superior to conventional MR protocols for the assessment of carotid plaque components, 118 with histology validation. However, it is not capable of identifying all features in carotid plaque, notably fibrous cap disruption, which is best assessed using CE protocols. 103 Furthermore, image quality was particularly susceptible to swallowing and pulsation artifacts, which needs to be overcome. Finally, the sequence was not compared with more recent multicontrast techniques such as SNAP.
Recently, quantitative MR mapping has gained particular interest in carotid artery plaque assessment. Carotid plaque quantification (with T1 and T2 mapping) was first introduced by Coolen et al 119 in a small feasibility study. Subsequently, the SNAP sequence was modified with the introduction of 3D golden-angle radial κ-space sampling quantitative vessel wall T1 mapping, a sequence known as GOAL-SNAP. 48 Total scan time was ≈5 minutes with an isotropic spatial resolution of 0.8 mm. This was extended further to include simultaneous 3D quantitative T1 and T2 mapping of the carotid artery (termed SIMPLE) in <10 minutes. 120 The advantage of quantitative mapping is that atherosclerotic plaque progression and regression can be assessed much more objectively and reproducibly, which is particularly useful in serial imaging, whereby instead of classifying plaques into hypointensity, hyperintensity, and isointensity, in the future plaque components may be defined into a range of T1 and T2 values.
As with coronary plaque characterization sequences, these carotid plaque sequences are encouraging but require large-scale clinical validation before they can be standardized into clinical practice. With this regard, the outcome of the AQUAMARINE EPA/DHA study is eagerly awaited.
Molecular MR Plaque Characterization
In recent years, there has been considerable research interest in targeted molecular imaging of vessel wall and atherosclerotic plaque. For a more extensive review of this topic, please refer to the publications by Phinikaridou et al, 121 Bender et al, 122 and Norenberg et al. 123 The main noninvasive molecular imaging modalities for plaque assessment include MRI, positron emission tomography (PET), and single photon emission computed tomography. Compared with PET and single photon emission computed tomography, MRI offers a significantly higher spatial resolution, improved soft tissue contrast and avoids ionizing radiation. However, because of the lower sensitivity of MRI, it requires a substantially higher in vivo concentration of the labeled molecular probe for a viable detection and quantification of the probe.
The most commonly used molecular MR probes can be categorized into 2 main groups, (1) T1-shortening paramagnetic gadolinium-based probes and (2) T2-shortening superparamagnetic (iron-oxide-based) nanoparticles. 122, 123 These molecular probes enable targeted imaging at all stages of atherosclerosis, from early endothelial dysfunction and activation, 124, 125 inflammation, 126,127 ECM (extracellular matrix) formation, [128] [129] [130] through to necrotic lipid core, [131] [132] [133] fibrous cap formation, 134 and plaque rupture. [135] [136] [137] This provides the unique opportunity for the early detection of atherosclerosis at a morphological, functional and biological level, while being able to individually target the features of the most vulnerable plaques. It also allows objective monitoring of plaque progression/regression following treatment.
Endothelial Dysfunction
Endothelial dysfunction occurs early in the atherosclerotic process, leading to reduced nitric oxide availability, impaired vasodilation, increased vascular permeability, and influx of atherogenic proteins. 121 An albumin-binding contrast agent, gadofosveset has been demonstrated to noninvasively monitor changes in endothelial permeability (as a surrogate of blood-albumin leakage) of the brachiocephalic and carotid artery in high-fat diet fed apoE −/− mice in vivo. 125 Furthermore, in a small patient population with symptomatic carotid atherosclerosis, Lobbes et al 138 observed significantly increased gadofosveset uptake.
VCAM (vascular cell adhesion molecules) facilitates the adhesion and extravasation of proinflammatory cells out of the blood and into the vessel wall. These molecules are, therefore, interesting targets in MR molecular plaque imaging. Indeed VCAM-1 targeting probes (eg, VINP-28) have successfully imaged the aortic root of atherosclerotic mice. 124, 139, 140 Furthermore, atheromata of atorvastatin-treated mice displayed reduced probe (VINP-28) uptake and VCAM-1 expression.
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Extracellular Matrix
The ECM (eg, collagen and elastin) constitutes a major component of the atherosclerotic plaque 141 and is associated with neoangiogenesis and unstable plaques. 142 A low-molecular-weight elastin-specific gadolinium-based MR contrast agent (elastinspecific magnetic resonance molecular imaging agent) has enabled MRI of all stages of atherosclerosis in an apoE −/− mouse model of atherosclerosis. 129 Successful translation in swine models of aortic and coronary atherosclerosis has also been feasible. 128, 130 By measuring the signal-to-noise ratio of elastin-specific magnetic resonance molecular imaging agent, it is possible to clinically assess overall plaque burden and stability. Other studies have successfully imaged the ECM using collagen-specific probes (EP3533-HDL and CNA-35).
143-145
Macrophages
Macrophages play a crucial role in the atherosclerotic cascade and can be targeted with ultrasmall superparamagnetic iron oxide particles stabilized with either steric (eg, dextran) or electrostatic (eg, citrate) coating. 121 These nanoparticles are phagocytosed by macrophages and subsequently accumulate in plaques. In an experimental study of the aortic wall of rabbits, Ruehm et al 146 demonstrated increased ultrasmall superparamagnetic iron oxide particle uptake in hyperlipidemic rabbits, with associated increased iron particles within plaque embedded macrophages on histology. In a subsequent clinical study of 11 symptomatic patients scheduled for carotid endarterectomy, Kooi et al 147 found increased ultrasmall superparamagnetic iron oxide particle uptake primarily in macrophages within the plaques confirmed on histology and electron microscopy analysis. On further analysis of plaque type, ultrasmall superparamagnetic iron oxide particle was found in 75% of ruptured or rupture-prone plaques but only in 7% of stable plaques.
In a different approach, Amirbekian et al 127 used gadolinium-loaded immunomicelles targeted against macrophage scavenger receptors. At 24 hours postinjection, immunomicelles provided a 79% increase in signal intensity of atherosclerotic aortas in ApoE −/− mice compared with only 34% using untargeted micelles and no enhancement using gadolinium alone. Confocal laser-scanning microscopy revealed colocalization between fluorescent immunomicelles and macrophages in plaques.
Neovascularization
As the atherosclerotic plaque develops, new blood vessels form which promotes plaque instability and is associated with intraplaque hemorrhage. 121, 123, 148, 149 It has been shown in preclinical porcine and rabbit models of atherosclerosis that gadofosveset trisodium, an albumin-binding MR probe can successfully image neovascularization as confirmed on histology. 150, 151 Unlike normal endothelial cells, during neovascularization activated endothelial cells express unique surface marker proteins such as αvβ3-integrin, which can be targeted with MR probes. 121, 123, 152 Using this approach, neovascularization has been demonstrated in several preclinical studies using gadolinium-loaded nanoparticles 153, 154 and has been used to monitor the local response to treatment.
155,156
Fibrin
Fibrin is heavily involved in thrombus formation and is found on the surface of vulnerable atherosclerotic plaques. 123, 133 It is, therefore, an important target for molecular vulnerable plaque imaging. Indeed, gadolinium labeled fibrin nanoparticles and small peptides (eg, EP-2104R) have successfully imaged thrombus and intraplaque fibrin in animal models of jugular vein, aorta, pulmonary, and coronary arteries. 135, 136, 157, 158 EP-2104R has also been translated in clinical studies of patients, successfully visualizing thrombus in the cardiovascular system. 159 Significantly less probe concentration is required because of the higher relaxivity of EP-2104R compared with nontargeted conventional contrast agents like gadolinium-DTPA. 121 
Proteolytic Enzymes
Proteolytic enzymes such as MMPs (matrix metalloproteinases) contribute to plaque vulnerability and are, therefore, an interesting target for MR probes. 123, 141, 160 Successful imaging of MMPs has been demonstrated in animal models of atherosclerosis using an MMP inhibitor conjugated to a gadolinium chelate (P947). 161, 162 MPO (Myeloperoxidase) is a leukocyte-derived enzyme that catalyzes the formation of a number of reactive oxidant species and is involved in the initiation, propagation, and acute complication phases of the atherosclerotic process. 163 In a study of the aortic wall of New Zealand White rabbits fed a high cholesterol diet using bis-5-hydroxytryptamide diethylenetriamine pentaacetate gadolinium (MPO(Gd)) contrast agent, Ronald et al 164 successfully demonstrated the feasibility of imaging MPO.
Lipids
The abundant lipid content of atherosclerotic plaques represents an ideal target for molecular MR probes. In a study of hyperlipidaemic rabbits, gadofluorine M (a lipophilic, macrocyclic, and chelate of gadolinium) showed a high accumulation in atherosclerotic plaques. 131 Furthermore, it has been shown that gadofluorine M uptake is increased in areas of plaque neovascularization. 165 In another approach, recombinant reconstituted HDL (high-density lipoprotein) nanoparticles (rHDL) conjugated with a carboxyfluorescein-labeled apolipoprotein E-derived lipopeptide, P2fA2 preferentially accumulated in lipid and macrophage-rich regions of plaque, in a murine model of atherosclerosis. 126 However, the use of these probes has so far mainly been restricted to preclinical animal studies or small in vivo human feasibility studies. One of the main reasons for this is the significantly higher dose of molecular probe required compared with nuclear techniques such as PET or single photon emission computed tomography, which is associated with potential side effects. The lack of comprehensive and costly safety/toxicology studies for the majority of these probes has prevented American and European approval agencies from issuing licenses for the clinical use of these agents. Nevertheless, improvements in molecular probe technology such as the use of nanoparticles and binding affinity of probes have lowered the dosage for these agents, enabling the licensing of some probes such as gadofosveset and ferumoxytol.
Hybrid Molecular Imaging (PET/CT and PET/MR)
By exploiting the high sensitivity of PET (low probe dosage), combined with the high spatial resolution of CT/MRI, hybrid imaging modalities are developing into a promising tool for the early detection and monitoring of atherosclerotic plaque. The most promising tracers used in PET plaque imaging are 18F-fluorodeoxyglucose (FDG) and 18F-sodium fluoride (NaF). FDG accumulates in metabolically active substrates, such as proinflammatory macrophages in vulnerable plaques. The relative difference in FDG uptake in normal vessel wall versus vulnerable plaque can be readily quantified using PET. 166 This has been validated histologically [167] [168] [169] [170] and in larger clinical studies. [171] [172] [173] [174] [175] [176] Indeed, it has been shown that increased FDG uptake in carotid plaques is associated with increased risk of stroke recurrence, independent on the degree of stenosis. 177 The use of PET/CT FDG uptake in plaques was translated to the coronary arteries. [178] [179] [180] [181] It has also been shown in several studies that FDG could be used to monitor therapeutic interventions such as statin therapy. 182, 183 However, the high myocardial uptake of FDG often limits the accurate assessment of coronary plaque FDG uptake, thus leading to the investigation of NaF. It can detect areas of microcalcification, an early inflammatory driven atherosclerotic process via the promotion of osteoblast-like cells, 184, 185 with significantly less myocardial uptake. Derlin et al 186 showed a significant correlation between NaF PET uptake and areas of arterial calcification. They also showed NaF uptake in carotid plaques of asymptomatic patients was significantly associated with cardiovascular risk factors. 187 Similarly, Dweck et al 188 showed that higher coronary NaF uptake was significantly associated with coronary atherosclerosis, CT coronary calcium score, higher rates of prior cardiovascular events, angina, and higher Framingham risk scores. Furthermore, coronary and carotid NaF uptake was shown to be significantly associated with culprit ruptured plaque, as opposed to FDG uptake, which was commonly obscured by myocardial uptake and where discernible, there were no differences between culprit and nonculprit plaque. 189 However, CT based hybrid imaging has limitations. First, the patient is exposed to 2 separate sources of radiation; one from the radiotracer itself and another dose from the CTA/ CTCA, giving an average of up to 14 mSv of radiation per scan. 190, 191 Second, CT has limited tissue characterization compared with MRI and is, therefore, less useful at distinguishing individual plaque components. 190 Third, PET/CT is vulnerable to misalignment as the CT and PET components are acquired sequentially. 192 Finally, CT is dependent on nephrotoxic contrast agents, whereas MRI overcomes this by exploiting noncontrast sequences.
With this in mind, recent advances in simultaneous PET/ MR hybrid imaging offers huge potential in atherosclerotic plaque imaging, in both carotid and coronary arteries. Furthermore, a lower dose of radiotracer could be injected and matched to the duration of the MRI scan, thus reducing radiation exposure. 193 However, motion-related image degradation, long acquisition times, and MR attenuation correction need to be overcome. In a feasibility study, Robson et al 191 proved the concept of simultaneous PET/MR coronary FDG/NaF imaging using a novel 3D free-breathing golden-angle radial motion-insensitive MR attenuation correction map. Compared with the breath-held sequence, this produced superior image quality with significantly less artifacts. Increasing the number of iterations further improved the image quality. The average radiation dose was 7.2 mSv, half the effective radiation dose in PET/CT. The same study also confirmed the superiority of NaF in coronary uptake and detection compared with FDG.
Recently, Munoz et al 194 combined a beat-to-beat image navigator-based 2D translational motion correction with a bin-to-bin 3D nonrigid motion correction for simultaneous free-breathing CMRA and PET FDG myocardial viability scanning. Despite a significantly shorter acquisition time, no significant difference was observed in terms of vessel length or sharpness compared with diaphragmatic navigator gating. Furthermore, motion correction improved image quality for both CMRA and PET (in terms of vessel and myocardial sharpness), compared with uncorrected reconstructions. The same group subsequently tested this sequence in 14 patients with CAD. 195 Motion correction improved both CMRA (vessel sharpness and lumen delineation) and FDG PET images (increased FDG myocardial signal, reduced noise, improved delineation of myocardial viability defects). Average acquisition time was ≈11 minutes, which was incorporated into the clinical waiting time required for conventional late gadolinium enhancement imaging. It would be interesting to assess this technique for NaF/FDG molecular imaging of coronary plaque. Figure 2 demonstrates the multifaceted potential of MRI as a single imaging modality in cardiovascular disease. 46, 48, 115, 129, 134, 191, [195] [196] [197] [198] [199] [200] [201] 
Conclusions and Future Directions
Despite enormous progress in the pharmacological and interventional treatment and primary prevention of cardiovascular disease, atherosclerosis remains a major global public health burden with devastating consequences. Over the past 2 decades, imaging of atherosclerosis has shifted away from direct luminography to a more comprehensive multifaceted assessment of lumen, vessel wall, plaque burden, and vulnerability. Among a crowd of imaging techniques, including OCT, intravascular ultrasound, X-ray angiography, CT, PET, single photon emission computed tomography, and ultrasound, MRI is emergency as a promising imaging modality of choice. It has several advantages including its versatility, noninvasiveness, nonionizing radiation, and excellent soft tissue characterization abilities. Technological advances in spatial resolution, motion correction, image acceleration, and single scan multicontrast sequences have put MRI on the verge of widespread clinical atherosclerosis imaging.
With further clinical validation of novel multicontrast sequences and molecular plaque imaging, MRI could establish itself as the gold standard in vivo imaging modality for the early detection and serial imaging of coronary and carotid atherosclerosis.
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